Download FREE Report Sample
Download Free sampleFavipiravir, sold under the brand name Avigan, is an antiviral medication used to treat influenza in Japan. It is also being studied to treat a number of other viral infections. Like the experimental antiviral drugs (T-1105 and T-1106), it is a pyrazinecarboxamide derivative. It is being developed and manufactured by Toyama Chemical (Fujifilm group) and was approved for medical use in Japan in 2014. In 2016, Fujifilm licensend API for it to Zhejiang Hisun Pharmaceutical Co. of China. It became a generic drug in 2019.
Favipiravir Market contains market size and forecasts of Favipiravir in global, including the following market information:
Global Favipiravir Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global Favipiravir Market Sales, 2017-2022, 2023-2028, (K Units)
Global top five Favipiravir companies in 2021 (%)
The global Favipiravir market was valued at 352.7 million in 2021 and is projected to reach US$ 67 million by 2028, at a CAGR of -21.1% during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Brand Drug Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Favipiravir include ChemRar Group, Glenmark, Fujifilm, Dr. Reddy, R-Pharma, Cipla, Lupin, Sun Pharma and Hisun Pharm. etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Favipiravir manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Favipiravir Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Favipiravir Market Segment Percentages, by Type, 2021 (%)
Brand Drug
Generic Drug
Global Favipiravir Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Favipiravir Market Segment Percentages, by Application, 2021 (%)
Influenza Viruses
COVID-19
Others
Global Favipiravir Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Favipiravir Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Favipiravir revenues in global market, 2017-2022 (Estimated), ($ millions)
Key companies Favipiravir revenues share in global market, 2021 (%)
Key companies Favipiravir sales in global market, 2017-2022 (Estimated), (K Units)
Key companies Favipiravir sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
ChemRar Group
Glenmark
Fujifilm
Dr. Reddy
R-Pharma
Cipla
Lupin
Sun Pharma
Hisun Pharm
Speak to our Custom Research Team and get the Custom Research in a budget
Custom ResearchFrequently Asked Questions ?
A license granted to one user. Rules or conditions might be applied for e.g. the use of electric files (PDFs) or printings, depending on product.
A license granted to multiple users.
A license granted to a single business site/establishment.
A license granted to all employees within organisation access to the product.
Upto Working 24 to 48 hrs
Upto 72 hrs max - Weekends and Public Holidays
Online Payments with PayPal and CCavenue
Wire Transfer/Bank Transfer
Hard Copy
Industry Market SizeSWOT AnalysisIndustry Major PlayersRevenue ForecastsHistorical and Forecast GrowthProfitability Analysis
